Verona Pharma seeks EMEA OK for RPL554 trials
UK-based Verona Pharma says it has initiated preliminary discussions with the European Medicines Agency (EMEA) in an effort to gain approval to conduct clinical trials of its allergic respiratory disease drug candidate RPL554. The firm said that it is in the process of preparing its submission dossier to support the application.
Verona added that RPL554 may represent a real step forward in the treatment of allergic respiratory conditions, including asthma, as it is does not utilize the steroids or beta agonists responsible for the side effects associated with currently-available medications.
The company's chief executive, Michael Walker, said that, while final analysis of toxicology data is yet to be completed, results produced so far suggest that the are no major toxicity issues associated with the drug. If approval is forthcoming, Verona plans to conduct combined Phase I/IIa trials in healthy patients suffering from mild, stable asthma in an effort to further confirm RPL554's safety and efficacy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze